Description: Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Home Page: www.nexalin.com
NXL Technical Analysis
1776 Yorktown
Houston,
TX
77056
United States
Phone:
713 660 1100
Officers
| Name | Title |
|---|---|
| Mr. Mark White | Pres, CEO & Director |
| Dr. David Owens M.D. | Chief Medical Officer & Director |
| Mr. John Patrick Claude | Co-Founder and Director of Engineering & Devel. |
| Ms. Marilyn Elson | Chief Financial Officer |
| Mr. Joel Bradus | Director of Sales & Marketing |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5432 |
| Price-to-Sales TTM: | 6.6843 |
| IPO Date: | 2022-09-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |